Dexamethasone downregulates caveolin-1 causing muscle atrophy via inhibited insulin signaling

Journal of Endocrinology

Volumn 225, Issue 1, 2015, Pages 27-37

  Son, Young Hoon ^a   Lee, Seok Jin ^a   Lee, Ki Baek ^a   Lee, Jin Haeng ^a   Jeong, Eui Man ^a   Chung, Sun Gun ^a   Park, Sang Chul ^a   Kim, In Gyu ^a  

^a Seoul National University College of Medicine   (South Korea)

Author keywords

C2C12 myotube; Caveolin 1; Glucocorticoid; Insulin signaling; Muscle atrophy

Indexed keywords

ADENOVIRUS VECTOR; CAVEOLIN 1; DEXAMETHASONE; INSULIN; INSULIN RECEPTOR; INSULIN RECEPTOR ALPHA; INSULIN RECEPTOR SUBSTRATE 1; MESSENGER RNA; SMALL INTERFERING RNA; UNCLASSIFIED DRUG; ISOPROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CAV1 GENE; CONTROLLED STUDY; DELETION MUTANT; DOWN REGULATION; GASTROCNEMIUS MUSCLE; GENE; GENE EXPRESSION; HOMEOSTASIS; HORMONE RESPONSIVE ELEMENT; MALE; MOUSE; MUSCLE ATROPHY; MYOTUBE; NONHUMAN; PRIORITY JOURNAL; PROMOTER REGION; SIGNAL TRANSDUCTION; SITE DIRECTED MUTAGENESIS; TRANSCRIPTION REGULATION; ANIMAL; C57BL MOUSE; CELL LINE; CHEMICALLY INDUCED; DRUG EFFECTS; GENE EXPRESSION REGULATION; METABOLISM; PHYSIOLOGY; RNA INTERFERENCE;

ANIMALS; CAVEOLIN 1; CELL LINE; DEXAMETHASONE; GENE EXPRESSION REGULATION; INSULIN; MALE; MICE; MICE, INBRED C57BL; MUSCULAR ATROPHY; PROTEIN ISOFORMS; RNA INTERFERENCE; SIGNAL TRANSDUCTION;

EID: 84929393838     PISSN: 00220795     EISSN: 14796805     Source Type: Journal    
DOI: 10.1530/JOE-14-0490     Document Type: Article

References (37)

1. Attaix D & Baracos VE 2010 MAFbx/Atrogin-1 expression is a poor index of muscle proteolysis. Current Opinion in Clinical Nutrition and Metabolic Care 13 223-224. (doi:10.1097/MCO.0b013e328338b9a6)
2. Austin ED, Ma L, LeDuc C, Berman Rosenzweig E, Borczuk A, Phillips JA III, Palomero T, Sumazin P, Kim HR, Talati MH et al. 2012 Whole exome sequencing to identify a novel gene (caveolin-1) associated with human pulmonary arterial hypertension. Circulation. Cardiovascular Genetics 5 336-343. (doi:10.1161/CIRCGENETICS.111.961888)
3. Baehr LM, Furlow JD & Bodine SC 2011 Muscle sparing in muscle RING finger 1 null mice: response to synthetic glucocorticoids. Journal of Physiology 589 4759-4776. (doi:10.1113/jphysiol.2011.212845)
4. van Batenburg MF, Li H, Polman JA, Lachize S, Datson NA, Bussemaker HJ & Meijer OC 2010 Paired hormone response elements predict caveolin-1 as a glucocorticoid target gene. PLoS ONE 5 e8839. (doi:10.1371/journal.pone.0008839)
5. Bonaldo P & Sandri M 2013 Cellular and molecular mechanisms of muscle atrophy. Disease Models & Mechanisms 6 25-39. (doi:10.1242/dmm.010389)
6. Boscher C & Nabi IR 2012 Caveolin-1: role in cell signaling. Advances in Experimental Medicine and Biology 729 29-50. (doi:10.1007/978-1-4614-1222-9_3)
7. Cao H, Alston L, Ruschman J & Hegele RA 2008 Heterozygous Cav1 frameshift mutations (MIM 601047) in patients with atypical partial lipodystrophy and hypertriglyceridemia. Lipids in Health and Disease 7 3. (doi:10.1186/1476-511X-7-3)
8. Clarke BA, Drujan D, Willis MS, Murphy LO, Corpina RA, Burova E, Rakhilin SV, Stitt TN, Patterson C, Latres E et al. 2007 The E3 ligase MuRF1 degrades myosin heavy chain protein in dexamethasonetreated skeletal muscle. Cell Metabolism 6 376-385. (doi:10.1016/j.cmet.2007.09.009)
9. Cohen AW, Hnasko R, Schubert W & Lisanti MP 2004 Role of caveolae and caveolins in health and disease. Physiological Reviews 84 1341-1379. (doi:10.1152/physrev.00046.2003)
10. Dostert A & Heinzel T 2004 Negative glucocorticoid receptor response elements and their role in glucocorticoid action. Current Pharmaceutical Design 10 2807-2816. (doi:10.2174/1381612043383601)
11. Drab M, Verkade P, Elger M, Kasper M, Lohn M, Lauterbach B, Menne J, Lindschau C, Mende F, Luft FC et al. 2001 Loss of caveolae, vascular dysfunction, and pulmonary defects in caveolin-1 gene-disrupted mice. Science 293 2449-2452. (doi:10.1126/science.1062688)
12. Fernandez MA, Albor C, Ingelmo-Torres M, Nixon SJ, Ferguson C, Kurzchalia T, Tebar F, Enrich C, Parton RG & Pol A 2006 Caveolin-1 is essential for liver regeneration. Science 313 1628-1632. (doi:10.1126/science.1130773)
13. Galbiati F, Volonte D, Minetti C, Chu JB & Lisanti MP 1999 Phenotypic behavior of caveolin-3 mutations that cause autosomal dominant limb girdle muscular dystrophy (LGMD-1C). Retention of LGMD-1C caveolin-3 mutants within the golgi complex. Journal of Biological Chemistry 274 25632-25641. (doi:10.1074/jbc.274.36.25632)
14. Gazzerro E, Sotgia F, Bruno C, Lisanti MP & Minetti C 2010 Caveolinopathies: from the biology of caveolin-3 to human diseases. European Journal of Human Genetics 18 137-145. (doi:10.1038/ejhg.2009.103)
15. Glass DJ 2010 Signaling pathways perturbing muscle mass. Current Opinion in Clinical Nutrition and Metabolic Care 13 225-229. (doi:10.1097/MCO.0b013e32833862df)
16. Hansen CG & Nichols BJ 2010 Exploring the caves: cavins, caveolins and caveolae. Trends in Cell Biology 20 177-186. (doi:10.1016/j.tcb.2010.01.005)
17. Igarashi J, Hashimoto T, Shoji K, Yoneda K, Tsukamoto I, Moriue T, Kubota Y & Kosaka H 2013 Dexamethasone induces caveolin-1 in vascular endothelial cells: implications for attenuated responses to VEGF. American Journal of Physiology. Cell Physiology 304 C790-C800. (doi:10.1152/ajpcell.00268.2012)
18. Kim CA, Delepine M, Boutet E, El Mourabit H, Le Lay S, Meier M, Nemani M, Bridel E, Leite CC, Bertola DR et al. 2008 Association of a homozygous nonsense caveolin-1 mutation with Berardinelli-Seip congenital lipodystrophy. Journal of Clinical Endocrinology and Metabolism 93 1129-1134. (doi:10.1210/jc.2007-1328)
19. Kim HS, Kim HJ, Kim YS, Park SC, Harris R& Kim CK 2009 Caveolin, GLUT4 and insulin receptor protein content in human arm and leg muscles. European Journal of Applied Physiology 106 173-179. (doi:10.1007/s00421-009-1001-1)
20. Koh A, Lee MN, Yang YR, Jeong H, Ghim J, Noh J, Kim J, Ryu D, Park S, Song P et al. 2013 C1-Ten is a protein tyrosine phosphatase of insulin receptor substrate 1 (IRS-1), regulating IRS-1 stability and muscle atrophy. Molecular and Cellular Biology 33 1608-1620. (doi:10.1128/MCB.01447-12)
21. Kuo T, Harris CA & Wang JC 2013 Metabolic functions of glucocorticoid receptor in skeletal muscle. Molecular and Cellular Endocrinology 380 79-88. (doi:10.1016/j.mce.2013.03.003)
22. Matthews L, Berry A, Ohanian V, Ohanian J, Garside H & Ray D 2008 Caveolin mediates rapid glucocorticoid effects and couples glucocorticoid action to the antiproliferative program. Molecular Endocrinology 22 1320-1330. (doi:10.1210/me.2007-0154)
23. Menconi M, Fareed M, O'Neal P, Poylin V, Wei W & Hasselgren PO 2007 Role of glucocorticoids in the molecular regulation of muscle wasting. Critical Care Medicine 35 S602-S608. (doi:10.1097/01.CCM.0000279194.11328.77)
24. Menconi M, Gonnella P, Petkova V, Lecker S & Hasselgren PO 2008 Dexamethasone and corticosterone induce similar, but not identical, muscle wasting responses in cultured L6 and C2C12 myotubes. Journal of Cellular Biochemistry 105 353-364. (doi:10.1002/jcb.21833)
25. Oh YS, Khil LY, Cho KA, Ryu SJ, Ha MK, Cheon GJ, Lee TS, Yoon JW, Jun HS & Park SC 2008 A potential role for skeletal muscle caveolin-1 as an insulin sensitivity modulator in ageing-dependent non-obese type 2 diabetes: studies in a new mouse model. Diabetologia 51 1025-1034. (doi:10.1007/s00125-008-0993-0)
26. Oh YS, Lee TS, Cheon GJ, Jang IS, Jun HS & Park SC 2011 Modulation of insulin sensitivity and caveolin-1 expression by orchidectomy in a nonobese type 2 diabetes animal model. Molecular Medicine 17 4-11. (doi:10.2119/molmed.2009.00105)
27. Ohsawa Y, Toko H, Katsura M, Morimoto K, Yamada H, Ichikawa Y, Murakami T, Ohkuma S, Komuro I & Sunada Y 2004 Overexpression of P104L mutant caveolin-3 in mice develops hypertrophic cardiomyopathy with enhanced contractility in association with increased endothelial nitric oxide synthase activity. Human Molecular Genetics 13 151-157. (doi:10.1093/hmg/ddh014)
28. Oshikawa J, Otsu K, Toya Y, Tsunematsu T, Hankins R, Kawabe J, Minamisawa S, Umemura S, Hagiwara Y & Ishikawa Y 2004 Insulin resistance in skeletal muscles of caveolin-3-null mice. PNAS 101 12670-12675. (doi:10.1073/pnas.0402053101)
29. Polge C, Heng AE, Jarzaguet M, Ventadour S, Claustre A, Combaret L, Bechet D, Matondo M, Uttenweiler-Joseph S, Monsarrat B et al. 2011 Muscle actin is polyubiquitinated in vitro and in vivo and targeted for breakdown by the E3 ligase MuRF1. FASEB Journal 25 3790-3802. (doi:10.1096/fj.11-180968)
30. Razani B, Engelman JA, Wang XB, Schubert W, Zhang XL, Marks CB, Macaluso F, Russell RG, Li M, Pestell RG et al. 2001 Caveolin-1 null mice are viable but show evidence of hyperproliferative and vascular abnormalities. Journal of Biological Chemistry 276 38121-38138.
31. Razani B, Combs TP, Wang XB, Frank PG, Park DS, Russell RG, Li M, Tang B, Jelicks LA, Scherer PE et al. 2002 Caveolin-1-deficient mice are lean, resistant to diet-induced obesity, and show hypertriglyceridemia with adipocyte abnormalities. Journal of Biological Chemistry 277 8635-8647. (doi:10.1074/jbc.M110970200)
32. Schakman O, Gilson H & Thissen JP 2008 Mechanisms of glucocorticoidinduced myopathy. Journal of Endocrinology 197 1-10. (doi:10.1677/ JOE-07-0606)
33. Schakman O, Kalista S, Barbe C, Loumaye A & Thissen JP 2013 Glucocorticoid-induced skeletal muscle atrophy. International Journal of Biochemistry & Cell Biology 45 2163-2172. (doi:10.1016/j.biocel.2013.05.036)
34. Schubert W, Sotgia F, Cohen AW, Capozza F, Bonuccelli G, Bruno C, Minetti C, Bonilla E, Dimauro S & Lisanti MP 2007 Caveolin 1(K/K)- and caveolin 2(K/K)-deficient mice both display numerous skeletal muscle abnormalities, with tubular aggregate formation. American Journal of Pathology 170 316-333. (doi:10.2353/ajpath.2007.060687)
35. Shimizu N, Yoshikawa N, Ito N, Maruyama T, Suzuki Y, Takeda S, Nakae J, Tagata Y, Nishitani S, Takehana K et al. 2011 Crosstalk between glucocorticoid receptor and nutritional sensor mTOR in skeletal muscle. Cell Metabolism 13 170-182. (doi:10.1016/j.cmet.2011.01.001)
36. Turney MK & Kovacs WJ 2001 Function of a truncated glucocorticoid receptor form at a negative glucocorticoid response element in the proopiomelanocortin gene. Journal of Molecular Endocrinology 26 43-49. (doi:10.1677/jme.0.0260043)
37. Zhao W, Qin W, Pan J, Wu Y, Bauman WA & Cardozo C 2009 Dependence of dexamethasone-induced Akt/FOXO1 signaling, upregulation of MAFbx, and protein catabolism upon the glucocorticoid receptor. Biochemical and Biophysical Research Communications 378 668-672. (doi:10.1016/j.bbrc.2008.11.123)